Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies

Journal of Pharmaceutical Sciences

Volumn 102, Issue 5, 2013, Pages 1578-1587

  Wallace, Stephanie J ^a   Nation, Roger L ^a   Li, Jian ^a   Boyd, Ben J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Azithromycin; Colistin; Colloid; Controlled release; Encapsulation; antiinfectives; Liposome

Indexed keywords

AZITHROMYCIN; COLISTIN; LIPOSOME;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL; CONCENTRATION RESPONSE; DRUG DETERMINATION; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; PHYSICAL CHEMISTRY;

EID: 84876325172     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23508     Document Type: Article

References (55)

1. Bergen PJ, Tsuji BT, Bulitta JB, Forrest A, Jacob J, Sidjabat HE, Paterson DL, Nation RL, Li J. 2012. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 55(12):5685-5695.
2. Deris ZZ, Yu HH, Davis K, Soon R, Jacob J, Ku CK, Poudyal A, Bergen PJ, Tsuji BT, Bulitta JB, Forrest A, Paterson DL, Velkov T, Li J, Nation RL. 2012. Colistin and doripenem combination is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro PK/PD model. Antimicrob Agents Chemother 56:5103-5112.
3. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. 2006. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 27(3):224-228.
4. Blondeau JM. 2002. The evolution and role of macrolides in infectious diseases. Expert Opin Pharmacother 3(8):1131-1151.
5. Abu-Gharbieh E, Vasina V, Poluzzi E, De Ponti F. 2004. Antibacterial macrolides: A drug class with a complex pharmacological profile. Pharm Res 50(3):211-222.
6. Gale EF, Cundliffe E, Reynolds PE, Richmond MH, Waring MJ, Eds. 1981. The molecular basis of antibiotic action. London: John Wiley & Sons.
7. Hancock RE, Speert DP. 2000. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and impact on treatment. Drug Resist Updat 3(4):247-255.
8. Hauser AR, Sriram P. 2005. Severe Pseudomonas aeruginosa infections. Tackling the conundrum of drug resistance. Postgrad Med 117(1):41-48.
9. Vaara M. 1992. Agents that increase the permeability of the outer membrane. Microbiol Rev 56(3):395-411.
10. Tamaoki J, Takeyama K, Tagaya E, Konno K. 1995. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 39(8):1688-1690.
11. Gotfried MH. 2004. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 125(2 Suppl):52S-60S; quiz 60S-61S.
12. Kawamura-Sato K, Iinuma Y, Hasegawa T, Horii T, Yamashino T, Ohta M. 2000. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agents Chemother 44(10):2869-2872.
13. Nalca Y, Jansch L, Bredenbruch F, Geffers R, Buer J, Haussler S. 2006. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: A global approach. Antimicrob Agents Chemother 50(5):1680-1688.
14. Gomez J, Banos V, Simarro E, Lorenzo Cruz M, Ruiz Gomez J, Latour J, Garcia Martin E, Canteras M, Valdes M. 2000. Prospective, comparative study (1994-1998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD. Rev Esp Quimioter 13(4):379-383.
15. Blasi F, Bonardi D, Aliberti S, Tarsia P, Confalonieri M, Amir O, Carone M, Di Marco F, Centanni S, Guffanti E. 2010. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther 23(3):200-207.
16. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, 3rd Campbell PW. 2003. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 290(13):1749-1756.
17. Mestres C, Alsina MA, Busquets MA, Muranyi I, Reig F. 1998. Interaction of colistin with lipids in liposomes and monolayers. Int J Pharm 160(1):99-107.
18. Wallace SJ, Li J, Nation RL, Prankerd RJ, Velkov T, Boyd BJ. 2010. Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: Implications for solution stability and solubilization. J Phys Chem B 114(14):4836-4840.
19. Kirby C, Gregoriadis G. 1983. The effect of lipid composition of small unilamellar liposomes containing melphalan and vincristine on drug clearance after injection into mice. Biochem Pharmacol 32(4):609-615.
20. Wong MY, Chiu GN. 2010. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment. Anticancer Drugs 21(4):401-410.
21. Narayanan NK, Nargi D, Randolph C, Narayanan BA. 2009. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 125(1):1-8.
22. Harasym TO, Tardi PG, Harasym NL, Harvie P, Johnstone SA, Mayer LD. 2007. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Oncol Res 16(8):361-374.
23. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD. 2007. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta 1768(3):678-687.
24. Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. 2004. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 10(2):728-738.
25. Wallace SJ, Li J, Nation R L, Boyd BJ. 2012. Drug release from nanomedicines: Selection of appropriate encapsulation and release methodology. Drug Deliv Transl Res 2(4):284-292.
26. Wallace SJ, Li J, Nation RL, Prankerd RJ, Boyd BJ. 2012. Interaction of colistin and colistin methanesulfonate with liposomes: Colloidal aspects and implications for formulation. J Pharm Sci 101(9):3347-3359.
27. Fenske DB, Wong KF, Maurer E, Maurer N, Leenhouts JM, Boman N, Amankwa L, Cullis PR. 1998. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim Biophys Acta 1414(1-2):188-204.
28. Munic V, Kelneric Z, Mikac L, Erakovic Haber V. 2010. Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci 41(1):86-95.
29. Martindale W. 1989. Martindale: The extra pharmacopeia. 29th ed. London: The Pharmaceutical Press.
30. Li X, Hirsh DJ, Cabral-Lilly D, Zirkel A, Gruner SM, Janoff AS, Perkins WR. 1998. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta 1415(1):23-40.
31. Johnston MJ, Semple SC, Klimuk SK, Edwards K, Eisenhardt ML, Leng EC, Karlsson G, Yanko D, Cullis PR. 2006. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta 1758(1):55-64.
32. Johnston MJ, Edwards K, Karlsson G, Cullis PR. 2008. Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res 18(2):145-157.
33. Lasic DD. 1996. Doxorubicin in sterically stabilized liposomes. Nature 380(6574):561-562.
34. Yamauchi M, Tsutsumi K, Abe M, Uosaki Y, Nakakura M, Aoki N. 2007. Release of drugs from liposomes varies with particle size. Biol Pharm Bull 30(5):963-966.
35. Maurer N, Fenske DB, Cullis PR. 2001. Developments in liposomal drug delivery systems. Expert Opin Biol Ther 1(6):923-947.
36. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. 2008. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 97(11):4696-4740.
37. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. 2005. The liposomal formulation of doxorubicin. Methods Enzymol 391:71-97.
38. Almgren M, Edwards K, Karlsson G. 2000. Cryo-transmission electron microscopy of liposomes and related structures. Colloids Surf A 174(1-2):3-21.
39. Abraham SA, Edwards K, Karlsson G, Hudon N, Mayer LD, Bally MB. 2004. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release 96(3):449-461.
40. Zhigaltsev IV, Maurer N, Akhong QF, Leone R, Leng E, Wang J, Semple SC, Cullis PR. 2005. Liposome-encapsulated vincristine, vinblastine and vinorelbine: A comparative study of drug loading and retention. J Control Release 104(1):103-111.
41. Washington C. 1990. Drug release from microdisperse systems: A critical review. Int J Pharm 58(1):1-12.
42. Silvius JR. 1982. Thermotropic phase transitions of pure lipids in model membranes and their modification by membrane proteins. In Lipid protein interactions; Jost PC, Griffith OH, Eds. New York: Wiley Interscience, pp 239-281.
43. Mayhew E, Rustum YM, Szoka F, Papahadjopoulos D. 1979. Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes. Cancer Treat Rep 63(11-12):1923-1928.
44. Mayer LD, Bally MB, Hope MJ, Cullis PR. 1985. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 816(2):294-302.
45. Liang X, Mao G, Ng KY. 2004. Mechanical properties and stability measurement of cholesterol-containing liposome on mica by atomic force microscopy. J Colloid Interface Sci 278(1):53-62.
46. Berquand A, Fa N, Dufrene YF, Mingeot-Leclercq MP. 2005. Interaction of the macrolide antibiotic azithromycin with lipid bilayers: Effect on membrane organization, fluidity, and permeability. Pharm Res 22(3):465-475.
47. Berquand A, Mingeot-Leclercq MP, Dufrene YF. 2004. Real-time imaging of drug-membrane interactions by atomic force microscopy. Biochim Biophys Acta 1664(2):198-205.
48. Gandhi R, Pillai O, Thilagavathi R, Gopalakrishnan B, Kaul CL, Panchagnula R. 2002. Characterization of azithromycin hydrates. Eur J Pharm Sci 16(3):175-184.
49. Lee RJ, Wang S, Turk MJ, Low PS. 1998. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery. Biosci Rep 18(2):69-78.
50. Qiu L, Jing N, Jin Y. 2008. Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method. Int J Pharm 361(1-2):56-63.
51. Lee SC, Yuk HG, Lee DH, Lee KE, Hwang YI, Ludescher RD. 2002. Stabilization of retinol through incorporation into Liposomes. J Biochem Mol Biol 35(4):358-363.
52. Loukas YL, Vraka V, Gregoriades K. 1998. Drugs, in cyclodextrins, in liposomes: A novel approach to the chemical stability of drugs sensitive to hydrolysis. Int J Pharm 162:137-142.
53. Lee SC, Lee KE, Kim JJ, Lim SH. 2005. The effect of cholesterol in the liposome bilayer on the stabilization of incorporated retinol. J Liposome Res 15(3-4):157-166.
54. Burke TG, Gao X. 2004. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J Pharm Sci 83(7):967-969.
55. Zhang L, Dhillon P, Yan H, Farmer S, Hancock RE. 2000. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob Agents Chemother 44(12):3317-3321.